By PPN News Staff
The FDA revised the emergency use authorization (EUA) for baricitinib (Olumiant, Lilly) to enable its use alone for the treatment of COVID-19 in hospitalized adults and pediatric patients as young as 24 months.
Under the revised EUA, baricitinib does not have to be administered with remdesivir (Veklury, Gilead). Baricitinib alone can be given to hospitalized adults and children with COVID-19 who require supplemental oxygen, noninvasive or invasive mechanical ventilation, or